| |
Company
Roster
|
|
Total
Insiders : |
23 |
|
|
|
Total
Direct Shares :
|
11,552,642 |
|
|
Total
Indirect Shares :
|
11,840,824 |
| |
%
Held by Insiders:
|
18.62% |
|
|
| |
| Filer's Name |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
  Siegel Jay Philip |
|
|
0 |
|
0 |
| Nadav Eran |
|
|
0 |
|
0 |
| Stewart Stanford John |
|
|
0 |
|
0 |
| Holmes W Stephen |
10% Owner |
2013-10-16 |
0 |
2013-10-16 |
1,908,716 |
| Oronsky Arnold L |
Director |
2013-10-16 |
0 |
2014-02-18 |
1,708,716 |
| Coulter James G |
Former 10% Owner |
2013-10-16 |
0 |
2013-10-16 |
2,208,762 |
| Alta Embarcadero Biopharma Partners III Llc |
10% Owner |
2013-10-16 |
0 |
2013-10-16 |
2,013,509 |
| Galbraith Kenneth |
Director |
2020-09-09 |
0 |
2013-10-16 |
1,317,049 |
| Peters Jeffrey Stuart |
Senior VP and General Counsel |
2024-04-04 |
0 |
2019-02-06 |
0 |
| Fust Matthew K |
Director |
2019-02-06 |
500 |
|
0 |
| Cilinski Lynn |
VP, Controller and Treasurer |
2024-02-15 |
6,213 |
|
0 |
| Spitznagel Thomas |
Sr VP, Technical Ops |
2024-03-04 |
8,316 |
2019-02-06 |
0 |
| Eck Stephen L. |
Chief Medical Officer |
2024-02-15 |
9,798 |
2024-02-15 |
0 |
| Saran Atul |
SVP & General Counsel |
2017-04-28 |
16,986 |
|
0 |
| Hurwitz Edward |
Director |
2015-05-11 |
18,074 |
2014-02-18 |
1,704,996 |
| Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
2018-02-26 |
18,930 |
2014-08-18 |
0 |
| Risser Eric Blasius |
Chief Operating Officer |
2024-03-04 |
38,900 |
|
0 |
| Costa Paulo F |
Director |
2016-03-03 |
59,435 |
|
0 |
| Stein Kathryn E |
SVP, Product Dev. & Regulatory |
2016-01-07 |
95,555 |
|
0 |
| Bonvini Ezio |
Sr VP, Research & CSO |
2024-02-22 |
100,892 |
2015-09-22 |
7,550 |
| Karrels James |
SVP, CFO and Secretary |
2024-03-04 |
171,452 |
2016-01-29 |
100,331 |
| Koenig Scott |
President and CEO, Director |
2024-02-15 |
1,077,628 |
2019-01-03 |
871,195 |
| Bb Biotech Ag |
10% Owner |
2023-10-02 |
9,929,963 |
|
0 |
|
0.19 (1.32%) 
